SCI Pharmtech Joins Enel X Taiwan's Virtual Power Plant to Achieve a Triple Win in Resilience, Sustainability, and Profitability

As global supply chains place increasing emphasis on low-carbon manufacturing and green procurement, net zero has become a critical factor in maintaining competitiveness. The biotechnology and pharmaceutical sector faces significant decarbonization pressure while also needing to comply with stringent GMP requirements and maintain highly reliable power supply for precision manufacturing processes.

Enel X Taiwan, which obtained its "Specified Electricity Supplier" license earlier this year, announced that active pharmaceutical ingredient (API) manufacturer SCI Pharmtech, Inc. (SCI) has officially joined its Virtual Power Plant (VPP). Starting from the Q3 2026, SCI Pharmtech will integrate approximately 1 MW of flexible capacity from its backup power assets into Taipower's Energy Trading Platform for "Spinning Reserve Ancillary Services," supporting grid stability while maintaining production reliability and product quality.

Wei-Chun Weng, Chairperson of SCI Pharmtech, stated that the company has established comprehensive API manufacturing capabilities and focuses on international markets, with more than 90% of revenue generated from exports. "We introduced ESG management practices in 2003 and established an energy management team in 2025 to continuously evaluate and improve energy efficiency. Joining the VPP not only enhances our energy management capabilities but also represents a transition from passive energy conservation to actively creating energy value."

When a grid dispatch instruction is issued, Enel X's VPP will use an automated control system to seamlessly transfer part of SCI Pharmtech's grid load to on-site backup generation within 5 minutes, enabling up to one hour of grid support, without disrupting manufacturing operations.

Enel X Taiwan Chairman Wei-Ting Chen noted that pharmaceutical manufacturing requires extremely high standards for power quality and operational reliability. "Through VPP participation, enterprises can transform idle backup power assets into new revenue streams and reinvest these benefits into renewable energy procurement and sustainability initiatives," Chen said. The partnership demonstrates how high-energy and precision manufacturing industries can simultaneously achieve operational resilience, carbon reduction goals, and economic benefits through energy asset optimization.

【About Enel X Taiwan】
Enel X Taiwan, within the Enel Group, works with commercial and industrial companies so that they can choose profitable and sustainable energy management solutions, have full control of their energy assets, and achieve decarbonization goals, while increasing competitiveness and optimizing energy expenditure. As the leading Demand Response Virtual Power Plant in Taiwan, Enel X Taiwan manages over 280 MW of Demand Response capacity, supporting more than 160 commercial and industrial customers across 200 sites.

【About SCI Pharmtech】
SCI Pharmtech was established in Taiwan in 1987 by Switzerland-based Siegfried Group, a company with a 125-year history. The company specializes in the research, development, manufacturing, and marketing of intermediates, active pharmaceutical ingredients (APIs), and specialty chemicals. Its products are primarily exported to major pharmaceutical companies in Europe, the United States, and Japan, earning strong recognition from customers for their quality. The company's principal shareholder is the Mercuries & Associates Holding (MERCURIES), Supported by a strong shareholder base and an experienced management team, SCI Pharmtech has achieved steady business growth year after year and was listed on the Taiwan Stock Exchange in 2004.

Source: Enel X Taiwan
Compilation & Ttranslation: EnergyOMNI